TY - JOUR
T1 - Current gaps in sepsis immunology
T2 - new opportunities for translational research
AU - Rubio, Ignacio
AU - Osuchowski, Marcin F.
AU - Shankar-Hari, Manu
AU - Skirecki, Tomasz
AU - Winkler, Martin Sebastian
AU - Lachmann, Gunnar
AU - La Rosée, Paul
AU - Monneret, Guillaume
AU - Venet, Fabienne
AU - Bauer, Michael
AU - Brunkhorst, Frank M.
AU - Kox, Matthijs
AU - Cavaillon, Jean Marc
AU - Uhle, Florian
AU - Weigand, Markus A.
AU - Flohé, Stefanie B.
AU - Wiersinga, W. Joost
AU - Martin-Fernandez, Marta
AU - Almansa, Raquel
AU - Martin-Loeches, Ignacio
AU - Torres, Antoni
AU - Giamarellos-Bourboulis, Evangelos J.
AU - Girardis, Massimo
AU - Cossarizza, Andrea
AU - Netea, Mihai G.
AU - van der Poll, Tom
AU - Scherag, André
AU - Meisel, Christian
AU - Schefold, Joerg C.
AU - Bermejo-Martín, Jesús F.
N1 - Funding Information:
JCS reports grants from Orion Pharma, Abbott Nutrition International, B Braun Medical, The Centre Suisse d'Electronique et de Microtechnique, Edwards Lifesciences Services, Kenta Biotech, Maquet Critical Care, grants from Omnicare Clinical Research, Nestle, Pierre Fabre Pharma, Pfizer, Bard Medica, Abbott, Anandic Medical Systems, Pan Gas Healthcare, Bracco, Hamilton Medical, Fresenius Kabi, Getinge Group Maquet, Dräger, Teleflex Medical, Glaxo Smith Kline, Merck Sharp and Dohme, Eli Lilly, Baxter, Astellas, Astra Zeneca, Commonwealth Serum Laboratories Behring, Novartis, Covidien, and Nycomed, outside the submitted work. EJG-B has received financial support (paid to the University of Athens) from AbbVie USA, grants from Abbott, grants and personal fees from Biotest Germany, grants and personal fees from Brahms, grants and personal fees from InflaRx, personal fees from Medicines Company, personal fees from Merck Sharp and Dohme Greece, grants and personal fees from XBiotech, grants and personal fees from Astellas Pharma, grants from AxisShield, grants from bioMérieux, grants from FrameWork 7 program HemoSpec, grants from Horizon2020 Marie-Curie project European Sepsis Academy, outside the submitted work. JFB-M reports personal fees from Biotest, grants and personal fees from Thermo, grants from Inflammatix and from Instituto de Salud Carlos III [PI16/01156] outside the submitted work. He is also inventor in a patent on a sepsis biomarker (MMP8) owned by Thermo Fisher. MM-F reports a grant from Consejería de Educación de Castilla y Leon and Fondo social Europeo outside the submitted work. MS-H received the UK National Institute for Health Research Clinician Scientist Award ( CS-2016-16-011 ). GL is participant of the Clinician Scientist Program granted by the Berlin Institute of Health. RA is inventor of a patent on a sepsis biomarker owned by Thermo Fisher. AT reports fees as advisor from BIOTEST, outside the submitted work. FU has a patent “Delta-like ligand 1 for diagnosing severe infections” pending, and a patent “Diagnosis and risk stratification for fungal infections” pending. MAW has a patent “Delta-like ligand 1 for diagnosing severe infections” pending, a patent “Diagnosis and risk stratification for fungal infections” pending, and a patent “Biomarkers for the diagnosis of invasive fungal infections” pending. All other authors declare no competing interest.
Funding Information:
JCS reports grants from Orion Pharma, Abbott Nutrition International, B Braun Medical, The Centre Suisse d'Electronique et de Microtechnique, Edwards Lifesciences Services, Kenta Biotech, Maquet Critical Care, grants from Omnicare Clinical Research, Nestle, Pierre Fabre Pharma, Pfizer, Bard Medica, Abbott, Anandic Medical Systems, Pan Gas Healthcare, Bracco, Hamilton Medical, Fresenius Kabi, Getinge Group Maquet, Dr?ger, Teleflex Medical, Glaxo Smith Kline, Merck Sharp and Dohme, Eli Lilly, Baxter, Astellas, Astra Zeneca, Commonwealth Serum Laboratories Behring, Novartis, Covidien, and Nycomed, outside the submitted work. EJG-B has received financial support (paid to the University of Athens) from AbbVie USA, grants from Abbott, grants and personal fees from Biotest Germany, grants and personal fees from Brahms, grants and personal fees from InflaRx, personal fees from Medicines Company, personal fees from Merck Sharp and Dohme Greece, grants and personal fees from XBiotech, grants and personal fees from Astellas Pharma, grants from AxisShield, grants from bioM?rieux, grants from FrameWork 7 program HemoSpec, grants from Horizon2020 Marie-Curie project European Sepsis Academy, outside the submitted work. JFB-M reports personal fees from Biotest, grants and personal fees from Thermo, grants from Inflammatix and from Instituto de Salud Carlos III [PI16/01156] outside the submitted work. He is also inventor in a patent on a sepsis biomarker (MMP8) owned by Thermo Fisher. MM-F reports a grant from Consejer?a de Educaci?n de Castilla y Leon and Fondo social Europeo outside the submitted work. MS-H received the UK National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). GL is participant of the Clinician Scientist Program granted by the Berlin Institute of Health. RA is inventor of a patent on a sepsis biomarker owned by Thermo Fisher. AT reports fees as advisor from BIOTEST, outside the submitted work. FU has a patent ?Delta-like ligand 1 for diagnosing severe infections? pending, and a patent ?Diagnosis and risk stratification for fungal infections? pending. MAW has a patent ?Delta-like ligand 1 for diagnosing severe infections? pending, a patent ?Diagnosis and risk stratification for fungal infections? pending, and a patent ?Biomarkers for the diagnosis of invasive fungal infections? pending. All other authors declare no competing interest.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/12
Y1 - 2019/12
N2 - Increasing evidence supports a central role of the immune system in sepsis, but the current view of how sepsis affects immunity, and vice versa, is still rudimentary. The European Group on Immunology of Sepsis has identified major gaps that should be addressed with high priority, such as understanding how immunological alterations predispose to sepsis, key aspects of the immunopathological events during sepsis, and the long-term consequences of sepsis on patient's immunity. We discuss major unmet topics in those three categories, including the role of key immune cells, the cause of lymphopenia, organ-specific immunology, the dynamics of sepsis-associated immunological alterations, the role of the microbiome, the standardisation of immunological tests, the development of better animal models, and the opportunities offered by immunotherapy. Addressing these gaps should help us to better understand sepsis physiopathology, offering translational opportunities to improve its prevention, diagnosis, and care.
AB - Increasing evidence supports a central role of the immune system in sepsis, but the current view of how sepsis affects immunity, and vice versa, is still rudimentary. The European Group on Immunology of Sepsis has identified major gaps that should be addressed with high priority, such as understanding how immunological alterations predispose to sepsis, key aspects of the immunopathological events during sepsis, and the long-term consequences of sepsis on patient's immunity. We discuss major unmet topics in those three categories, including the role of key immune cells, the cause of lymphopenia, organ-specific immunology, the dynamics of sepsis-associated immunological alterations, the role of the microbiome, the standardisation of immunological tests, the development of better animal models, and the opportunities offered by immunotherapy. Addressing these gaps should help us to better understand sepsis physiopathology, offering translational opportunities to improve its prevention, diagnosis, and care.
UR - http://www.scopus.com/inward/record.url?scp=85073746610&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(19)30567-5
DO - 10.1016/S1473-3099(19)30567-5
M3 - Review article
C2 - 31630991
AN - SCOPUS:85073746610
SN - 1473-3099
VL - 19
SP - e422-e436
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -